Earnings Feed
Start Free
BOSTON SCIENTIFIC CORP·4

Feb 17, 7:09 PM ET

O'Sullivan Miriam 4

Research Summary

AI-generated summary

Updated

Boston Scientific (BSX) SVP Miriam O'Sullivan Exercises Options, Receives Awards

What Happened Miriam O'Sullivan, SVP & Chief Human Resources Officer at Boston Scientific (BSX), had several equity actions reported for 2026-02-12. The Form 4 shows conversion/exercise of derivative awards totaling 961 shares (reported both as acquired and disposed in the filing) and a tax-withholding disposition of 338 shares sold at $74.12 for $25,053. She was also granted awards totaling 4,722 and 11,143 shares (15,865 total awards) and received a separate option grant subject to vesting. The acquisitions are reported at $0.00 per share, which is typical for restricted stock unit (RSU) conversions/awards rather than a market purchase.

Key Details

  • Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (5 days after the transactions — outside the usual 2-business-day window for Form 4 filings).
  • Tax withholding: 338 shares disposed at $74.12 per share, net proceeds reported as $25,053 (code F).
  • Derivative activity: 961 shares reported as exercised/converted (code M) with both an “acquired” and a “disposed” entry in the filing.
  • Awards granted: 4,722 shares (A) and 11,143 shares (A) — total 15,865 awarded (reported at $0.00).
  • Shares owned after transaction: not provided in the supplied data.
  • Footnotes (from the filing):
    • F1: Each RSU represents a commitment to issue one share.
    • F2: One award vests in four equal annual installments beginning Feb 12, 2025.
    • F3: One award vests in four equal annual installments beginning Feb 12, 2027.
    • F4: Option grant vests in four equal annual installments beginning Feb 12, 2027.

Context The filing primarily reflects awarded/vested equity (RSUs/options) and tax withholding rather than an open-market sale or purchase. The $25k figure is the value of shares withheld/surrendered to satisfy tax obligations; this is routine for RSU vesting and does not necessarily indicate a discretionary sale. The awards and option grants are subject to future vesting schedules per the footnotes, so they do not represent immediately tradable stock for the full amounts reported.